UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $8
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $7 to $8.
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $7 to $8.